TGFB1 and cancer: A pan-cancer analysis showed that TGF-β signaling in CAFs activated “ECM-up” signaling, independent of CAFs or TGF-β activation, a predictor associated with anti-PD-1 resistance, even better than T Cellular inflammatory signaling and mutational burden (Chakravarthy et al., 2018).